Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis and Management of Acute and Chronic Lithium-Associated Nephrotoxicity.

Journal of the American Society of Nephrology : JASN·2026
Same author

Conventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) Workgroup.

Kidney international·2026
Same author

Cancer therapy and the kidney.

Kidney international·2026
Same author

The Cutting Edge: A Clinicopathology Minireview of Immunoglobulin A Nephropathy.

Glomerular diseases·2026
Same author

Biology of drug-induced acute nephrotoxicity: focus on the tubulointerstitium.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.

Nature reviews. Nephrology·2025
Same journal

KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

Kidney international·2026
Same journal

KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

Kidney international·2026
Same journal

A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease.

Kidney international·2026
Same journal

Asymptomatic serologic reactivation in patients with lupus nephritis in clinical remission: to treat or not to treat?

Kidney international·2026
Same journal

What does it mean to win? Interpreting hierarchical kidney outcomes in hypertension trials.

Kidney international·2026
Same journal

Resolving the VEGF paradox in DKD: VEGFR1 blockade shows promising renoprotection.

Kidney international·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

Bisphosphonate nephrotoxicity.

Mark A Perazella1, Glen S Markowitz

  • 1Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA.

Kidney International
|August 8, 2008
PubMed
Summary
This summary is machine-generated.

Intravenous bisphosphonates can cause kidney damage, but careful monitoring and dose adjustments can minimize risks. Ibandronate shows a safe renal profile, even in patients with impaired kidney function.

Related Experiment Videos

Last Updated: Jul 3, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

Area of Science:

  • Nephrology
  • Oncology
  • Endocrinology

Background:

  • Bisphosphonates are crucial for treating osteoporosis and bone metastases.
  • Intravenous (IV) bisphosphonates carry a risk of nephrotoxicity, dependent on dose and infusion time.
  • Zoledronate and pamidronate are common IV bisphosphonates with distinct nephrotoxicity patterns.

Purpose of the Study:

  • To review the nephrotoxicity profiles of bisphosphonates.
  • To highlight strategies for mitigating renal risks with IV bisphosphonates.
  • To evaluate the renal safety of ibandronate.

Main Methods:

  • Literature review of bisphosphonate use and associated nephrotoxicity.
  • Analysis of clinical data regarding zoledronate, pamidronate, and ibandronate.
  • Examination of dosing and monitoring guidelines for renal protection.

Main Results:

  • Oral bisphosphonates have low nephrotoxicity risk.
  • IV bisphosphonates (zoledronate, pamidronate) can cause acute tubular necrosis and glomerulosclerosis.
  • Strict adherence to monitoring and dose adjustment guidelines minimizes severe nephrotoxicity.
  • Ibandronate demonstrates a favorable renal safety profile, even in patients with pre-existing kidney disease.

Conclusions:

  • Nephrotoxicity from IV bisphosphonates is manageable with proper protocols.
  • Ibandronate offers a safer alternative regarding renal function.
  • Optimizing bisphosphonate therapy requires careful patient selection and monitoring.